Live·Open questions in longevity research
All news
Longevity researchTherapeutics

Developer of mitochondrial gene therapy proposes testing whether it can outperform mitochondrial transplantation and identifies findings that would weaken his hypothesis

18 November 2026· 261118009

Developer of mitochondrial gene therapy proposes testing whether it can outperform mitochondrial transplantation and identifies findings that would weaken his hypothesis

On November 13, Aging published an article by Patrick Sewell, who founded and holds an equity stake in Triple Helix Science, a company developing some of the gene therapies discussed. Taking physicist John Cramer's hypothesis as his starting point, Sewell compares transplantation of existing mitochondria with gene therapy intended to enable cells to maintain their own mitochondria.

Cramer set out his hypothesis in a book: damage accumulates in mitochondrial DNA, cells lose energy, and the other features of aging follow. He proposes large infusions of mitochondria as the treatment. “I am 91… We need whole-body rejuvenation, and we need it now,” he said in a press release from Mitrix Bio, which has already opened clinics offering experimental mitochondrial transplantation.

Sewell considers a 2004 experiment the strongest evidence that mitochondrial DNA damage can cause aging. The mice had a defective enzyme that copied this DNA without correcting errors: mutations accumulated, and the mice aged prematurely. To assess whether the same defect occurs during normal human aging, Sewell draws on a study of the genomes of about 750 thousand people. Mitochondrial DNA mutations in blood increase sharply after age 60, but many occur in only a small fraction of mitochondrial DNA copies and appear largely neutral. The study's authors link the increase to clonal hematopoiesis: the descendants of a single blood cell multiply, making a previously undetected mutation detectable.

Sewell describes aging as a network in which mitochondrial DNA damage is one component, alongside nuclear DNA breaks and senescent cells. Interventions targeting each of these have altered aging in mice. An intervention should therefore be assessed by whether it repairs a specific form of damage and corrects the associated tissue dysfunction.

For human transplantation, Sewell examines a study that retrospectively compared children with acute heart failure after surgery. Eight of the ten children who received their own mitochondria were weaned off mechanical heart and lung support, compared with four of the fourteen who did not undergo the procedure.

Sewell hypothesizes that introduced genes could provide sustained, controllable support for mitochondria, allowing gene therapy to outperform transplantation. One candidate is TERT, a protein component of telomerase, the enzyme that extends the ends of chromosomes. TERT has also been found in mitochondria, where it protected mitochondrial DNA in cell experiments. Viral delivery of the TERT gene extended median lifespan in mice by 13–24% without increasing cancer incidence, but continuous expression of the gene in another mouse line led to mammary cancer. Another candidate is TFEB, which activates autophagy, the breakdown of worn cellular components, including mitochondria. Excess TFEB in mouse kidneys caused cysts and tumors.

Sewell proposes testing each gene separately in cells to establish both its benefits and its mechanism of action. For TERT, this means separating its effects on chromosome ends from its effects within mitochondria. The next step would be to test a combination of genes in aged animals and determine whether gene therapy provides additional benefit after transplantation. Findings that would weaken his hypothesis include a gene changing molecular markers without improving tissue function; a decline in the proportion of mutant DNA caused by the death of cells carrying it; a combination performing no better than the best individual gene; and sustained gene expression accompanied by unacceptable pathology. The approaches could complement each other: transplantation could support tissue during an acute energy deficit, and a separately tested intervention could sustain that support.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#mitochondrial-dna#gene-therapy#mitochondrial-transplantation#tert#tfeb#aging